Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Share-based Compensation data on file, last reported at $11.9 million in Q1 2026.

• Quarterly Share-based Compensation fell 1.8% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.3 million (changed 0.38% YoY) and the FY2025 annual result came in at $51.5 million, down 3.97% from the prior year.
• Share-based Compensation declined to $11.9 million in Q1 2026 per ADPT's latest filing, from $12.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $17.3 million in Q2 2023, with the low at $11.9 million in Q1 2026.
• Average Share-based Compensation over 5 years is $13.8 million, with a median of $13.5 million recorded in 2024.
• Year-over-year, Share-based Compensation jumped 51.59% in 2022 and retreated 25.29% in 2024.
• Adaptive Biotechnologies' Share-based Compensation stood at $14.3 million in 2022, then advanced by 8.83% to $15.6 million in 2023, then slipped by 17.51% to $12.8 million in 2024, then declined by 0.87% to $12.7 million in 2025, then slipped by 6.23% to $11.9 million in 2026.
• Business Quant data shows ADPT's Share-based Compensation at $11.9 million in Q1 2026, $12.7 million in Q4 2025, and $13.3 million in Q3 2025.